Myelodysplastic syndromes (MDS)

Authors

  • Neysimelia Costa Villela Barretos Cancer Hospital, Barretos, SP, Brazil.
  • Patrícia Shimoda Ikeuti Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.
  • Simone de Castro Resende Franco Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil
  • Roseane Vasconcelos Gouveia Hospital Samaritano, São Paulo, SP, Brazil
  • Gustavo Zamperlini Hospital Samaritano, São Paulo, SP, Brazil
  • Luiz Fernando Lopes Barretos Cancer Hospital, Barretos, SP, Brazil.

DOI:

https://doi.org/10.46765/2675-374X.2021v2n4p127

Abstract

MDS in children is a rare group of hematopoietic stem cell clonal disorder. Allogeneic HSCT is the only curative treatment. HLA typing and the search for a compatible donor must be carried out upon diagnosis, for all patients.  However, patients with refractory cytopenia of childhood without an unfavorable karyotype can keep the disease stable for a long time. Thus, in the absence of transfusion dependence or severe neutropenia, a careful observation strategy without treatment is recommended. The treatment of children diagnosed with MDS with excess blasts remains a major challenge. Allogeneic HSCT is the only curative treatment, although the data published in the literature generally include a small number of patients, heterogeneously transplanted. For children with MDS secondary to therapy, despite HSCT, the evolution is generally unfavorable.

Author Biographies

Neysimelia Costa Villela, Barretos Cancer Hospital, Barretos, SP, Brazil.

MD. 

Member of the Brazilian Pediatric Myelodysplastic Syndrome Study Group.

Physician at the Pediatric Bone Marrow Transplant Unit, Barretos Cancer Hospital, Barretos, SP, Brazil.

Patrícia Shimoda Ikeuti, Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.  

Simone de Castro Resende Franco, Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil.

 

Roseane Vasconcelos Gouveia, Hospital Samaritano, São Paulo, SP, Brazil

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Hospital Samaritano, São Paulo, SP, Brazil. 

Gustavo Zamperlini, Hospital Samaritano, São Paulo, SP, Brazil

 

MD. Physician at the Pediatric Bone Marrow Transplant Unit, Hospital Samaritano, São Paulo, SP, Brazil. 

Luiz Fernando Lopes, Barretos Cancer Hospital, Barretos, SP, Brazil.

 

 Chairman of the Brazilian Pediatric Myelodysplastic Syndrome Study Group.

Director of Barretos Chindren´s Cancer Center.

Downloads

Published

11/30/2021

How to Cite

Costa Villela, N., Shimoda Ikeuti, P. ., de Castro Resende Franco, S. ., Vasconcelos Gouveia, R. ., Zamperlini, G. ., & Lopes, L. F. . (2021). Myelodysplastic syndromes (MDS). JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(4), 127. https://doi.org/10.46765/2675-374X.2021v2n4p127

Most read articles by the same author(s)